
Key figures in Lundbeck’s fourth quarterly disappointed, and as a consequence, the company’s full-year 2021 report was below expectations.
Compared with 2020, revenue is actually down. This is primarily due to an almost DKK 2bn (USD 307.3m) drop in sales of drug Northera, whose patent expired in February last year.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app